BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 26986171)

  • 1. Calculation of Blood Dose in Patients Treated With 131I Using MIRD, Imaging, and Blood Sampling Methods.
    Piruzan E; Haghighatafshar M; Faghihi R; Entezarmahdi SM
    Medicine (Baltimore); 2016 Mar; 95(11):e3154. PubMed ID: 26986171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. One size does not fit all: the merit of absorbed doses to the blood in 131I therapy for differentiated thyroid carcinoma.
    Fatholahi L; Tabeie F; Pashazadeh AM; Javadi H; Assadi M; Asli IN
    Health Phys; 2015 Jan; 108(1):53-8. PubMed ID: 25437520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pre-therapeutic blood dosimetry in patients with differentiated thyroid carcinoma using 124-iodine: predicted blood doses correlate with changes in blood cell counts after radioiodine therapy and depend on modes of TSH stimulation and number of preceding radioiodine therapies.
    Hartung-Knemeyer V; Nagarajah J; Jentzen W; Ruhlmann M; Freudenberg LS; Stahl AR; Bockisch A; Rosenbaum-Krumme SJ
    Ann Nucl Med; 2012 Nov; 26(9):723-9. PubMed ID: 22802008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blood dosimetry from a single measurement of the whole body radioiodine retention in patients with differentiated thyroid carcinoma.
    Hänscheid H; Lassmann M; Luster M; Kloos RT; Reiners C
    Endocr Relat Cancer; 2009 Dec; 16(4):1283-9. PubMed ID: 19628649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lung dosimetry for radioiodine treatment planning in the case of diffuse lung metastases.
    Song H; He B; Prideaux A; Du Y; Frey E; Kasecamp W; Ladenson PW; Wahl RL; Sgouros G
    J Nucl Med; 2006 Dec; 47(12):1985-94. PubMed ID: 17138741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone marrow dosimetry and safety of high 131I activities given after recombinant human thyroid-stimulating hormone to treat metastatic differentiated thyroid cancer.
    de Keizer B; Hoekstra A; Konijnenberg MW; de Vos F; Lambert B; van Rijk PP; Lips CJ; de Klerk JM
    J Nucl Med; 2004 Sep; 45(9):1549-54. PubMed ID: 15347723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Whole-remnant and maximum-voxel SPECT/CT dosimetry in
    Mínguez P; Flux G; Genollá J; Delgado A; Rodeño E; Sjögreen Gleisner K
    Med Phys; 2016 Oct; 43(10):5279-5287. PubMed ID: 28105713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lowest effective 131I activity for thyroid remnant ablation of differentiated thyroid cancer patients. Dosimetry-based model for estimation.
    Jentzen W; Moldovan AS; Ruhlmann M; Görges R; Bockisch A; Rosenbaum-Krumme S
    Nuklearmedizin; 2015; 54(3):137-43. PubMed ID: 25987357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiation dose to the testes after 131I therapy for ablation of postsurgical thyroid remnants in patients with differentiated thyroid cancer.
    Ceccarelli C; Battisti P; Gasperi M; Fantuzzi E; Pacini F; Gualdrini G; Pierantoni MC; Luciani A; Djokich D; Pinchera A
    J Nucl Med; 1999 Oct; 40(10):1716-21. PubMed ID: 10520714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Lungs absorbed dose in radioiodine therapy of differentiated thyroid carcinoma with diffuse pulmonary metastases].
    Liu B; Zeng Y; Wang J; Zhao Z; Mu D; Kuang A
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2010 Aug; 27(4):851-4. PubMed ID: 20842858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dosimetry in differentiated thyroid carcinoma (12-1402R).
    Minguez P; Genolla J; Celeiro JJ; Fombellida JC
    Med Phys; 2013 Jan; 40(1):012502. PubMed ID: 23298113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between cumulative radiation dose and salivary gland uptake associated with radioiodine therapy of thyroid cancer.
    Jentzen W; Schneider E; Freudenberg L; Eising EG; Görges R; Müller SP; Brandau W; Bockisch A
    Nucl Med Commun; 2006 Aug; 27(8):669-76. PubMed ID: 16829767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal.
    Hänscheid H; Lassmann M; Luster M; Thomas SR; Pacini F; Ceccarelli C; Ladenson PW; Wahl RL; Schlumberger M; Ricard M; Driedger A; Kloos RT; Sherman SI; Haugen BR; Carriere V; Corone C; Reiners C
    J Nucl Med; 2006 Apr; 47(4):648-54. PubMed ID: 16595499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Iodine kinetics and dosimetry in the salivary glands during repeated courses of radioiodine therapy for thyroid cancer.
    Liu B; Huang R; Kuang A; Zhao Z; Zeng Y; Wang J; Tian R
    Med Phys; 2011 Oct; 38(10):5412-9. PubMed ID: 21992360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiation dose assessments in radioiodine (131I) therapy. 1. The necessity for in vivo quantitation and dosimetry in the treatment of carcinoma of the thyroid.
    Schlesinger T; Flower MA; McCready VR
    Radiother Oncol; 1989 Jan; 14(1):35-41. PubMed ID: 2928556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 124I-PET dosimetry in advanced differentiated thyroid cancer: therapeutic impact.
    Freudenberg LS; Jentzen W; Görges R; Petrich T; Marlowe RJ; Knust J; Bockisch A
    Nuklearmedizin; 2007; 46(4):121-8. PubMed ID: 17690789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of Simplified Blood Dose Protocols for the Estimation of the Maximum Tolerable Activity in Thyroid Cancer Patients Undergoing Radioiodine Therapy Using 124I.
    Jentzen W; Bockisch A; Ruhlmann M
    J Nucl Med; 2015 Jun; 56(6):832-8. PubMed ID: 25858042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radioactivity of blood samples taken from thyroidectomized thyroid carcinoma patients after therapy with (131)I.
    Larkin A; Millan E; Noz M; Wagner S; Friedman K; Blum M
    Thyroid; 2011 Sep; 21(9):1009-12. PubMed ID: 21834682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unexpected effect of furosemide on radioiodine urinary excretion in patients with differentiated thyroid carcinomas treated with iodine 131.
    Matovic MD; Jankovic SM; Jeremic M; Tasic Z; Vlajkovic M
    Thyroid; 2009 Aug; 19(8):843-8. PubMed ID: 19519221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radioiodine therapy for well-differentiated thyroid cancer: a quantitative dosimetric evaluation for remnant thyroid ablation after surgery.
    Samuel AM; Rajashekharrao B
    J Nucl Med; 1994 Dec; 35(12):1944-50. PubMed ID: 7989975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.